Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer's disease progression
Xinyi Wang, Guangqiang Sun, Teng Feng, Jing Zhang, Xun Huang, Tao Wang, Zuoquan Xie, Xingkun Chu, Jun Yang, Huan Wang, Shuaishuai Chang, Yanxue Gong, Lingfei Ruan, Guanqun Zhang, Siyuan Yan, Wen Lian, Chen Du, Dabing Yang, Qingli Zhang, Feifei Lin, Jia Liu, Haiyan Zhang, Changrong Ge, Shifu Xiao, Jian Ding, Meiyu Geng, Xinyi Wang, Guangqiang Sun, Teng Feng, Jing Zhang, Xun Huang, Tao Wang, Zuoquan Xie, Xingkun Chu, Jun Yang, Huan Wang, Shuaishuai Chang, Yanxue Gong, Lingfei Ruan, Guanqun Zhang, Siyuan Yan, Wen Lian, Chen Du, Dabing Yang, Qingli Zhang, Feifei Lin, Jia Liu, Haiyan Zhang, Changrong Ge, Shifu Xiao, Jian Ding, Meiyu Geng
Abstract
Recently, increasing evidence has suggested the association between gut dysbiosis and Alzheimer's disease (AD) progression, yet the role of gut microbiota in AD pathogenesis remains obscure. Herein, we provide a potential mechanistic link between gut microbiota dysbiosis and neuroinflammation in AD progression. Using AD mouse models, we discovered that, during AD progression, the alteration of gut microbiota composition leads to the peripheral accumulation of phenylalanine and isoleucine, which stimulates the differentiation and proliferation of pro-inflammatory T helper 1 (Th1) cells. The brain-infiltrated peripheral Th1 immune cells are associated with the M1 microglia activation, contributing to AD-associated neuroinflammation. Importantly, the elevation of phenylalanine and isoleucine concentrations and the increase of Th1 cell frequency in the blood were also observed in two small independent cohorts of patients with mild cognitive impairment (MCI) due to AD. Furthermore, GV-971, a sodium oligomannate that has demonstrated solid and consistent cognition improvement in a phase 3 clinical trial in China, suppresses gut dysbiosis and the associated phenylalanine/isoleucine accumulation, harnesses neuroinflammation and reverses the cognition impairment. Together, our findings highlight the role of gut dysbiosis-promoted neuroinflammation in AD progression and suggest a novel strategy for AD therapy by remodelling the gut microbiota.
Conflict of interest statement
XYW, GQS, TF, JZ, XKC, JY, SSC, YXG, LFR, GQZ, SYY, WL, CD, DBY and CRG are full-time employees of Shanghai Green Valley Pharmaceutical Co., Ltd. The other authors declare no competing interests.
Figures
References
- Cummings J, Lee G, Ritter A, Zhong K. Alzheimer’s disease drug development pipeline: 2018. Alzheimer’s Dement. 2018;4:195–214.
- Kodamullil AT, et al. Trial watch: tracing investment in drug development for Alzheimer disease. Nat. Rev. Drug Discov. 2017;16:819. doi: 10.1038/nrd.2017.169.
- Honda K, Littman DR. The microbiota in adaptive immune homeostasis and disease. Nature. 2016;535:75–84. doi: 10.1038/nature18848.
- Thaiss CA, Zmora N, Levy M, Elinav E. The microbiome and innate immunity. Nature. 2016;535:65–74. doi: 10.1038/nature18847.
- Blander JM, Longman RS, Iliev ID, Sonnenberg GF, Artis D. Regulation of inflammation by microbiota interactions with the host. Nat. Immunol. 2017;18:851–860. doi: 10.1038/ni.3780.
- Cattaneo A, et al. Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly. Neurobiol. Aging. 2017;49:60–68. doi: 10.1016/j.neurobiolaging.2016.08.019.
- Vogt NM, et al. Gut microbiome alterations in Alzheimer’s disease. Sci. Rep. 2017;7:13537. doi: 10.1038/s41598-017-13601-y.
- Zhuang ZQ, et al. Gut microbiota is altered in patients with Alzheimer’s disease. J. Alzheimers Dis. 2018;63:1337–1346. doi: 10.3233/JAD-180176.
- Minter MR, et al. Antibiotic-induced perturbations in gut microbial diversity influences neuro-inflammation and amyloidosis in a murine model of Alzheimer’s disease. Sci. Rep. 2016;6:30028. doi: 10.1038/srep30028.
- Calvani R, et al. Of microbes and minds: a narrative review on the second brain aging. Front. Med. 2018;5:53. doi: 10.3389/fmed.2018.00053.
- DiCarlo G, Wilcock D, Henderson D, Gordon M, Morgan D. Intrahippocampal LPS injections reduce Abeta load in APP+PS1 transgenic mice. Neurobiol. Aging. 2001;22:1007–1012. doi: 10.1016/S0197-4580(01)00292-5.
- Herber DL, et al. Microglial activation is required for Abeta clearance after intracranial injection of lipopolysaccharide in APP transgenic mice. J. NeuroImmune Pharmacol. 2007;2:222–231. doi: 10.1007/s11481-007-9069-z.
- Bryson KJ, Lynch MA. Linking T cells to Alzheimer’s disease: from neurodegeneration to neurorepair. Curr. Opin. Pharmacol. 2016;26:67–73. doi: 10.1016/j.coph.2015.10.003.
- Cao W, Zheng H. Peripheral immune system in aging and Alzheimer’s disease. Mol. Neurodegener. 2018;13:51. doi: 10.1186/s13024-018-0284-2.
- Merlini M, Kirabali T, Kulic L, Nitsch RM, Ferretti MT. Extravascular CD3+ T cells in brains of Alzheimer disease patients correlate with tau but not with amyloid pathology: an immunohistochemical study. Neurodegener. Dis. 2018;18:49–56. doi: 10.1159/000486200.
- Kowalski K, Mulak A. Brain-gut-microbiota axis in Alzheimer’s disease. J. Neurogastroenterol. Motil. 2019;25:48–60. doi: 10.5056/jnm18087.
- Alkasir R, Li J, Li X, Jin M, Zhu B. Human gut microbiota: the links with dementia development. Protein Cell. 2017;8:90–102. doi: 10.1007/s13238-016-0338-6.
- Main BS, Minter MR. Microbial immuno-communication in neurodegenerative diseases. Front. Neurosci. 2017;11:151. doi: 10.3389/fnins.2017.00151.
- Prinz M, Priller J. The role of peripheral immune cells in the CNS in steady state and disease. Nat. Neurosci. 2017;20:136–144. doi: 10.1038/nn.4475.
- Sasaguri H, et al. APP mouse models for Alzheimer’s disease preclinical studies. EMBO J. 2017;36:2473–2487. doi: 10.15252/embj.201797397.
- He Z, et al. Amyloid-beta plaques enhance Alzheimer’s brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation. Nat. Med. 2018;24:29–38. doi: 10.1038/nm.4443.
- Chen C, et al. The prodrug of 7,8-dihydroxyflavone development and therapeutic efficacy for treating Alzheimer’s disease. Proc. Natl Acad. Sci. USA. 2018;115:578–583. doi: 10.1073/pnas.1718683115.
- Ulland TK, et al. TREM2 maintains microglial metabolic fitness in Alzheimer’s disease. Cell. 2017;170:649–663 e613. doi: 10.1016/j.cell.2017.07.023.
- Kimura R, Ohno M. Impairments in remote memory stabilization precede hippocampal synaptic and cognitive failures in 5XFAD Alzheimer mouse model. Neurobiol. Dis. 2009;33:229–235. doi: 10.1016/j.nbd.2008.10.006.
- Oakley H, et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer’s disease mutations: potential factors in amyloid plaque formation. J. Neurosci. 2006;26:10129–10140. doi: 10.1523/JNEUROSCI.1202-06.2006.
- Jawhar S, Trawicka A, Jenneckens C, Bayer TA, Wirths O. Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal Abeta aggregation in the 5XFAD mouse model of Alzheimer’s disease. Neurobiol. Aging. 2012;33:196 e129–140. doi: 10.1016/j.neurobiolaging.2010.05.027.
- Kanno T, Tsuchiya A, Nishizaki T. Hyperphosphorylation of Tau at Ser396 occurs in the much earlier stage than appearance of learning and memory disorders in 5XFAD mice. Behav. brain Res. 2014;274:302–306. doi: 10.1016/j.bbr.2014.08.034.
- Lever J, Krzywinski M, Altman N. Principal component analysis. Nat. Methods. 2017;14:641. doi: 10.1038/nmeth.4346.
- Heneka MT, et al. NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice. Nature. 2013;493:674–678. doi: 10.1038/nature11729.
- Krasemann S, et al. The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity. 2017;47:566–581 e569. doi: 10.1016/j.immuni.2017.08.008.
- Venegas C, et al. Microglia-derived ASC specks cross-seed amyloid-beta in Alzheimer’s disease. Nature. 2017;552:355–361. doi: 10.1038/nature25158.
- Sharon G, Sampson TR, Geschwind DH, Mazmanian SK. The central nervous system and the gut microbiome. Cell. 2016;167:915–932. doi: 10.1016/j.cell.2016.10.027.
- Tang Y, Le W. Differential roles of M1 and M2 microglia in neurodegenerative diseases. Mol. Neurobiol. 2016;53:1181–1194. doi: 10.1007/s12035-014-9070-5.
- Ajami B, et al. Single-cell mass cytometry reveals distinct populations of brain myeloid cells in mouse neuroinflammation and neurodegeneration models. Nat. Neurosci. 2018;21:541–551. doi: 10.1038/s41593-018-0100-x.
- Korin B, et al. High-dimensional, single-cell characterization of the brain’s immune compartment. Nat. Neurosci. 2017;20:1300–1309. doi: 10.1038/nn.4610.
- Mrdjen D, et al. High-dimensional single-cell mapping of central nervous system immune cells reveals distinct myeloid subsets in health, aging, and disease. Immunity. 2018;48:380–395 e386. doi: 10.1016/j.immuni.2018.01.011.
- Hamalainen H, et al. Distinct gene expression profiles of human type 1 and type 2 T helper cells. Genome Biol. 2001;2:RESEARCH0022. doi: 10.1186/gb-2001-2-7-research0022.
- Matarin M, et al. A genome-wide gene-expression analysis and database in transgenic mice during development of amyloid or tau pathology. Cell Rep. 2015;10:633–644. doi: 10.1016/j.celrep.2014.12.041.
- Francisco EC, Franco TT, Wagner R, Jacob-Lopes E. Assessment of different carbohydrates as exogenous carbon source in cultivation of cyanobacteria. Bioprocess Biosyst. Eng. 2014;37:1497–1505. doi: 10.1007/s00449-013-1121-1.
- Uhde A, et al. Glucosamine as carbon source for amino acid-producing corynebacterium glutamicum. Appl. Microbiol. Biotechnol. 2013;97:1679–1687. doi: 10.1007/s00253-012-4313-8.
- Ladeveze S, Laville E, Despres J, Mosoni P, Potocki-Veronese G. Mannoside recognition and degradation by bacteria. Biol. Rev. Camb. Philos. Soc. 2017;92:1969–1990. doi: 10.1111/brv.12316.
- Limoli, D. H., Jones, C. J. & Wozniak, D. J. Bacterial extracellular polysaccharides in biofilm formation and function. Microbiology spectrum3, 10.1128/microbiolspec.MB-0011-2014 (2015).
- Rooks MG, Garrett WS. Gut microbiota, metabolites and host immunity. Nat. Rev. Immunol. 2016;16:341–352. doi: 10.1038/nri.2016.42.
- Li L, et al. Evaluating in vitro culture medium of gut microbiome with orthogonal experimental design and a metaproteomics approach. J. Proteome Res. 2018;17:154–163. doi: 10.1021/acs.jproteome.7b00461.
- Zhang X, et al. Metaproteomics reveals associations between microbiome and intestinal extracellular vesicle proteins in pediatric inflammatory bowel disease. Nat. Commun. 2018;9:2873. doi: 10.1038/s41467-018-05357-4.
- Zhang X, et al. MetaPro-IQ: a universal metaproteomic approach to studying human and mouse gut microbiota. Microbiome. 2016;4:31. doi: 10.1186/s40168-016-0176-z.
- Chagoyen M, Pazos F. MBRole: enrichment analysis of metabolomic data. Bioinformatics. 2011;27:730–731. doi: 10.1093/bioinformatics/btr001.
- Xia J, Wishart DS. Using MetaboAnalyst 3.0 for comprehensive metabolomics data analysis. Curr. Protoc. Bioinforma. 2016;55:14 10 11–14 10 91. doi: 10.1002/cpbi.11.
- Liaw, A. W., M. Classification and regression by randomForest. R News, 18–22 (2002).
- Sinclair LV, et al. Control of amino-acid transport by antigen receptors coordinates the metabolic reprogramming essential for T cell differentiation. Nat. Immunol. 2013;14:500–508. doi: 10.1038/ni.2556.
- Schetters STT, Gomez-Nicola D, Garcia-Vallejo JJ, Van Kooyk Y. Neuroinflammation: microglia and T cells get ready to tango. Front. Immunol. 2017;8:1905. doi: 10.3389/fimmu.2017.01905.
- Benakis C, et al. Commensal microbiota affects ischemic stroke outcome by regulating intestinal gammadelta T cells. Nat. Med. 2016;22:516–523. doi: 10.1038/nm.4068.
- Faraco G, et al. Dietary salt promotes neurovascular and cognitive dysfunction through a gut-initiated TH17 response. Nat. Neurosci. 2018;21:240–249. doi: 10.1038/s41593-017-0059-z.
- Dodiya Hemraj B., Kuntz Thomas, Shaik Shabana M., Baufeld Caroline, Leibowitz Jeffrey, Zhang Xulun, Gottel Neil, Zhang Xiaoqiong, Butovsky Oleg, Gilbert Jack A., Sisodia Sangram S. Sex-specific effects of microbiome perturbations on cerebral Aβ amyloidosis and microglia phenotypes. The Journal of Experimental Medicine. 2019;216(7):1542–1560. doi: 10.1084/jem.20182386.
- Sochocka M, et al. The gut microbiome alterations and inflammation-driven pathogenesis of Alzheimer’s disease-a critical review. Mol. Neurobiol. 2019;56:1841–1851. doi: 10.1007/s12035-018-1188-4.
- Thomson P, Medina DA, Garrido D. Human milk oligosaccharides and infant gut bifidobacteria: molecular strategies for their utilization. Food Microbiol. 2018;75:37–46. doi: 10.1016/j.fm.2017.09.001.
- Remmelink E, Smit AB, Verhage M, Loos M. Measuring discrimination- and reversal learning in mouse models within 4 days and without prior food deprivation. Learn. Mem. 2016;23:660–667. doi: 10.1101/lm.042085.116.
- Vorhees CV, Williams MT. Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat. Protoc. 2006;1:848–858. doi: 10.1038/nprot.2006.116.
- Maecker HT, McCoy JP, Nussenblatt R. Standardizing immunophenotyping for the human immunology project. Nat. Rev. Immunol. 2012;12:191–200. doi: 10.1038/nri3158.
- Flaherty, S. & Reynolds, J. M. Mouse naive CD4+ T cell isolation and in vitro differentiation into T cell subsets. J. Visual. Exp.10.3791/52739 (2015).
Source: PubMed